New Phase 2 Clinical Trial Opens for Rare Leukemia/Lymphoma in Children
Off-the-shelf cellular therapy targets relapsed or refractory T-cell leukemia/lymphoma A potentially groundbreaking clinical trial is now open at Siteman Kids at St. Louis Children’s Hospital to evaluate an allogeneic, off-the-shelf cellular therapy designed to treat patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/LBL). Siteman Kids is one of […]
Whole Genome Sequencing for AML/MDS Risk Stratification
ChromoSeq now covered by Medicare; Two Clinical Trials Also Open Two novel clinical trials for patients diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are open and enrolling patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The clinical trials are utilizing a breakthrough whole-genome […]
Washington University to test ‘homegrown’ universal CAR T-cell therapy at Siteman Cancer Center
In early 2022, immunotherapy specialists at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine will begin a new clinical trial using off-the-shelf CAR T-cell therapy for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The therapy, developed by Washington University researchers at Siteman, incorporates many facets of the School […]